Description

The fund invests in equity securities as well as ADRs of companies substantially in the same proportion as its underlying index. These securities are listed on stock exchanges in North America, and are classified as life sciences companies (including those involved in biopharmaceuticals, medical manufacturing, distribution, and bio products) as well as other companies with significant business activities in the marijuana industry. Rebalanced quarterly, the portfolio is market-cap-weighted with 10% maximum capping for each constituent.